

**PennHIP Report**

Referring Veterinarian: Dr Jeffrey Brubaker  
 Clinic Name: Stayton Veterinary Hospital  
 Email: jbrubaker@staytonveterinary.com  
 Clinic Address: 1308 North First Ave  
 Stayton, OR 97383  
 Phone: (503) 769-7387  
 Fax: (503) 769-9832

**Patient Information**

Client: Garfias, Sydney  
 Tattoo Num:  
 Patient Name: San  
 Patient ID: 30215  
 Reg. Name: Moro Mononoke of Ten Peak  
 Registration Num:  
 PennHIP Num: 124570  
 Microchip Num: 985112007913371  
 Species: Canine  
 Breed: WHITE SWISS SHEPHERD DOG  
 Date of Birth: 13 Dec 2016  
 Age: 23 months  
 Sex: Female  
 Weight: 66 lbs/29.9 kgs  
 Date of Study: 20 Nov 2018  
 Date Submitted: 20 Nov 2018  
 Date of Report: 21 Nov 2018

**Findings**

Distraction Index (DI): Right DI = 0.33, Left DI = 0.29.

Osteoarthritis (OA): **No radiographic evidence of OA for either hip.**


Cavitation/Other Findings: No cavitation present.

**Interpretation**

Distraction Index (DI): The laxity ranking is based on the hip with the greater laxity (larger DI). In this case the DI used is 0.33.

OA Risk Category: The DI is between 0.31 and 0.49. This patient is at mild risk for hip OA.

Distraction Index Chart:

**WHITE SWISS SHEPHERD DOG**

**BREED STATISTICS:** This interpretation is based on a cross-section of 55 canine patients of the WHITE SWISS SHEPHERD DOG breed in the AIS PennHIP database. The gray strip represents the central 90% range of DIs (0.22 - 0.67) for the breed. The breed average DI is 0.37 (solid square). The patient DI is the solid circle (0.33).

**SUMMARY:** The degree of laxity (DI = 0.33) falls within the central 90% range of DIs for the breed. This amount of hip laxity places the hip at a mild risk to develop hip OA. **No radiographic evidence of OA for either hip.**

**INTERPRETATION AND RECOMMENDATIONS:** No OA/Mild Risk: Low risk to develop radiographic evidence of hip OA early in life, however OA may manifest after 6 years of age or later. Risk of OA increases as DI, age, body weight, and activity level increase. OA susceptibility is breed specific, larger breeds being more susceptible.

**Recommendations:** Evidence-based strategies to lower the risk of dogs developing hip OA or to treat those having OA fall into 5 modalities.\* For detailed information, consult these documents.\* Use any or all of these modalities as needed:

- 1) For acute or chronic pain prescribe NSAID PO short or long term. Amantadine can be added if response is marginal or if a neuropathic component to the pain is suspected.
- 2) Optimize body weight, keep lean, at BCS = 5/9.
- 3) Prescribe therapeutic exercise at intensities that do not precipitate lameness.
- 4) Administer polysulfated glycosaminoglycans IM or SQ, so-called DMOAD.
- 5) Feed an EPA-rich prescription diet preventatively for dogs at risk for OA or therapeutically for dogs already showing radiographic signs of OA.

At the present time there is inadequate evidence to confidently recommend any of the many other remedies to prevent or treat OA. Studies are in progress. Consider repeating radiographs at periodic intervals to determine the rate of OA progression and adjust treatment accordingly. Older dogs may show clinical signs such as chronic pain, reluctance to go stairs or jump onto the bed, and stiffness particularly after resting. It is unlikely that end-stage hip disease will develop for dogs at this risk level so surgical therapy for the pain of hip OA would rarely be indicated.

**Breeding Recommendations:** Please consult the PennHIP Manual.

\* From WSAVA Global Pain Council Guidelines and the 2015 AAHA/AAFP Pain Management Guidelines

**COMMENTS:**

None